FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 303:1-5 July 3, 1980 Number 1 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To determine the prognosis after hospitalization of patients hospitalized with acute chest pain in a coronary-care unit, we undertook a prospective study of 211 consecutive admissions to the Stanford Coronary Care Unit. On the basis of predetermined criteria, 16 patients were found to have noncardiac chest pain, and myocardial infarction was ruled out in 89, one of whom died in the hospital. Infarction was documented in 84 others, six of whom died in the hospital. Prospective follow-up after hospitalization was carried out in the 88 patients in whom infarction was ruled out and in the 78 patients who survived infarction. The rate of myocardial infarction or death was 8.0 per cent at six months and 21.6 per cent at a mean of 27.8 months of follow-up for patients who had infarction ruled out, as compared with 7.7 per cent at six months and 21.8 per cent at a mean of 27.8 months of follow-up for those who had a documented infarction during the initial hospitalization. Cardiomegaly, congestive heart failure, and angina after discharge from the hospital tended to increase the risk of morbidity and mortality in both groups. The patient hospitalized with acute ischemic chest pain without evolution of a myocardial infarction has a six to 24-month prognosis similar to that of the patient hospitalized with an acute infarction, and therefore requires similar diagnostic and therapeutic assessment.

This article has been cited by other articles:

• Rosalki, S. B., Roberts, R., Katus, H. A., Giannitsis, E., Ladenson, J. H., Apple, F. S. (2004). Cardiac Biomarkers for Detection of Myocardial Infarction: Perspectives from Past to Present. Clin. Chem. 50: 2205-2213 [Abstract] [Full Text]  
• Tate, J. R., Badrick, T., Koumantakis, G., Potter, J. M., Hickman, P. E. (2002). Reporting of Cardiac Troponin Concentrations. Clin. Chem. 48: 2077-2080 [Full Text]  
• Alpert, J.S. (2000). The not so obvious truth. Eur Heart J 21: 180-181  
• DeAngelis, L. M. (1998). Brain tumor therapy: New horizons, new hope. Neurology 50: 1209-1210 [Full Text]  
• Perry, J. R., DeAngelis, L. M., Schold, S. C. Jr, Burger, P. C., Brem, H., Brown, M. T., Curran, W. J., Scott, C. B., Prados, M. D., Kaplan, R., Cairncross, J. G. (1997). Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 49: 912-917 [Full Text]  
• Muller-Bardorff, M., Hallermayer, K., Schroder, A., Ebert, C., Borgya, A., Gerhardt, W., Remppis, A., Zehelein, J., Katus, H. A. (1997). Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin. Chem. 43: 458-466 [Abstract] [Full Text]  
• Oksaranta, O., Tarvonen, S., Ilonen, J., Poikonen, K., Reunanen, M., Panelius, M., Salonen, R. (1996). T-cell subpopulations in the cerebrospinal fluid and peripheral blood of patients with multiple sclerosis: A follow-up study. Neurology 47: 1542-1545 [Abstract] [Full Text]  
• Devinsky, O., Fisher, R. (1996). Ethical use of placebos and provocative testing in diagnosing nonepileptic seizures. Neurology 47: 866-870 [Full Text]  
• Dropcho, E. J., Soong, S.-j. (1996). The prognostic impact of prior low grade histology in patients with anaplastic gliomas: A case-control study. Neurology 47: 684-690 [Abstract] [Full Text]  
• Skoulas, A., Alloo, R. G., Weisbart, M. H., Manelis, M. A. (1981). Duration of Hospital Stay and Post- Myocardial Infarction Morbidity and Mortality: A Kaiser-Permanente Experience. ANGIOLOGY 32: 509-516 [Abstract]